Anti-venom Market Demand, Consumption Ratio, Industry Challenges And Future Forecasts To 2026 | BTG plc. Laboratorios Silanes, CSL Limited, Pfizer, Merck, Bharat Serums and Vaccines, Haffkine Bio-Pharmaceutical Corporation

Anti-venom is a medication majorly used to treat snake bites and it can also be used to treat bites from scorpions, spiders or other reptiles. It is made by fractionating the blood of the donor (horse or sheep), which is hyper immunized with snake venom. These products are available in either lyophilized or liquid forms. Anti-venom is the only effective therapy against snake bites and apart from lifesaving, they also save patients from cell and tissue necrosis, thus helping save vital organs. As per World Health Organization (WHO) fact sheet, 4.5 to 5.4 million people are bitten by snakes, every year, globally, out of which 1.8 to 2.7 million people develop clinical illnesses after snake bites and up to 81,000 to 1, 38,000 people die from such snake bites. Snake bite causes around 400,000 amputations and other permanent disabilities, annually.

You may also be interested in these Insights Access PDF@ https://www.coherentmarketinsights.com/insight/request-pdf/1249

South Asia and Africa are expected to drive growth of the anti-venom market, owing to higher incidence of snakebites
Growth of the anti-venom market is expected to be driven by South Asia and sub-Saharan African countries due to highest incidence of snake bites in these regions. As per WHO statistics, in India, 3.8 million people are bitten by snakes and 46,900 people die every year. In sub-Saharan Africa, around 7,000 to 20,000 people die annually from snake bites. Highest incidence is recorded in rural and peri-urban areas, where croppers and livestock workers live. However, growing urbanization is resulting in the loss of habitat for many snake species due to deforestation, thus drawing them towards area inhabited by humans, in turn, increasing the incidence of snakebites.

However, high costs associated with anti-venom products (due to high manufacturing cost) hinders growth of the anti-venom market. Lack of access to anti-venom products is also one of the major constraints for market growth. According to WHO, most of the sub-Saharan African region does not locally produce anti-venom, thus the populace in this region relies on traditional treatment to treat snakebites. Countries in this region often face chronic shortage of anti-venom production, thus, creating opportunities for market players to enter the anti-venom market.

Market Segmentation of the Global Anti-venom Market

On the basis of anti-venom type:
Monovalent (Hyper immunizing venom obtained from single species)
Polyvalent (Hyper immunizing venom from two or more species)

On the basis of product type:
Snake anti venom
Scorpion anti-venom
Spider anti venom
Other anti-venom products

The anti-venom market is dominated mostly by the producers from emerging economies such as India, Brazil, and Mexico. In 2014, Sanofi Pasteur announced that it would not produce its anti-venom product Fav-Afrique (mostly sold in African countries), which is one of the most effective polyvalent anti-venom products. This was due to tough competition from low cost manufacturers from emerging economies such as India, Brazil, and Mexico.
Key players present in the anti-venom market include Haffkine Bio-Pharmaceutical Corporation Ltd., Bharat Serums and Vaccines Ltd, Vins Bioproducts Limited, CSL Behring, Vacsera, Rare Therapeutics, Instituto Bioclon S.A.de C.V., and Incepta Vaccine Ltd.

Get Sample Copy of This Research Report: https://www.coherentmarketinsights.com/insight/request-sample/1249

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com

This release was published on openPR.